Kevin Conroy: We have focused relentlessly on Cologuard in the US. And as a result of that, we have developed great scale, reach and a ton of learnings. Applying that outside the US, we haven’t provided guidance as to when Cologuard would be brought outside the US. There’s clearly a need though. Just if you take a look at the EU market, it is a significant opportunity because the colon cancer mortality rate is significantly higher in Europe than it is in the US. Screening — maybe 30% of the population is up-to-date with colorectal cancer screen. So there’s an opportunity there. We’ll wait until some point in the future to talk about what our plans are outside the US. Certainly the learnings that we have developed in the US and the focus that we’ve had will help as we export Cologuard outside the US.
Jeff Elliott: And Liza, this is Jeff. Just to add to Kevin’s answer here. That international foundation is strong today. To put some perspective around it, we have a team of over 200 people in our international team, really top managed team here. We do business in over 100 countries already. This has taken us years in fact, probably over a decade, to build up this global footprint. And what that’s getting us is strong double-digit growth for years to come. The base of revenue today is already over $150 million. With good margins, it is a nicely profitable business, largely on one product, and as Kevin talked about, adding more and more products to that will help improve the profitability. And this is one of the core reasons why back in 2019 that we sought out to really come together with Genomic Health, is this high-quality international footprint.
This sets us up for years to come to provide really a strong important leg of growth and importantly to help patients around the world.
Operator: We’ll take our next question from Alex Nowak with Craig-Hallum Capital.
Alex Nowak: Okay. Great. Good afternoon, everyone. I was wondering what are the latest time lines for Cologuard blood. And this is a question I’ve had since the Analyst Day. And since the Cologuard 2.0 data was so good, why pursue a different assay in blood altogether for colon cancer screening. Everett mentioned docs only have a few minutes with their patients. So does adding the test — does it potentially risk making the conversations a bit confusing for primary care in particular? Thanks.
Kevin Conroy: So Cologuard blood will be — or what we call our CRC blood test, it has been named yet. We expect middle of next year to have data. What is the role for a blood test. The role for a blood test, we believe, will be for patients who refuse a frontline recommended screening test per USPSTF guidelines. And there are people who refuse other — all forms of colon cancer screening. And for those patients, a blood test, which is clearly not going to be as good as detecting precancerous polyps or Stage 1 cancers as other frontline screening tests, there’s still a role for that, and it’s important to screen those individuals. We happen to know who those patients are. People have chosen Cologuard over colonoscopy and yet haven’t returned to test.
So it’s a discrete relatively small population on a percentage basis, but large in terms of the sheer number of people in the US, measuring in the millions. So we’ll be able to engage with those patients if they have not completed a Cologuard test, not completed a colonoscopy, work with their healthcare provider that we have a deep relationship with, work with the health system to do our best to get those patients screened. And so that’s — our mission is to eradicate colon cancer, and that’s going to — this is going to be an important tool that we have to help achieve that mission.
Operator: Thank you. And that does conclude today’s question-and-answer session as well as presentation. Thank you for your participation today, and you may now disconnect.
